Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: Bimatoprost cutaneous solution 0.03%

First Posted Date: 2015-07-22

Last Posted Date: 2018-08-14

Lead Sponsor: Allergan

Target Recruit Count: 1699

Registration Number: NCT02505776

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

Phase 4

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: Preserved Bimatoprost 0.01%
Drug: Tafluprost Unit Dose Preservative Free 15microgram/ml

First Posted Date: 2015-06-15

Last Posted Date: 2016-05-12

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 67

Registration Number: NCT02471105

Locations: 🇨🇭
Clinical Research Centre Momorial A. de Rotschild, Geneve, Switzerland
🇮🇹
Bietti Foundation, Rome, Italy
🇮🇹
San Paolo Hospital, Milan, Italy

and more 4 locations

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Not Applicable

Completed

Conditions: Nail Growth Cessation
Intraocular Pressure

Interventions: Drug: Bimatoprost 0.01%

First Posted Date: 2015-05-19

Last Posted Date: 2019-12-13

Lead Sponsor: Northwestern University

Target Recruit Count: 45

Registration Number: NCT02448043

Locations: 🇺🇸
David J. Palmer, MD, Glenview, Illinois, United States

Stop Retinal Ganglion Cell Dysfunction Study

Phase 3

Completed

Conditions: Glaucoma

Interventions: Drug: Latanoprost
Drug: Bimatoprost
Drug: Travoprost
Drug: Timolol
Drug: Dorzolamide
Drug: Brinzolamide
Drug: Acetazolamide
Drug: Methazolamide

First Posted Date: 2015-03-17

Last Posted Date: 2024-10-10

Lead Sponsor: University of Miami

Target Recruit Count: 500

Registration Number: NCT02390284

Locations: 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States

Dose-Ranging Study of the Bimatoprost Ocular Insert

Phase 2

Completed

Conditions: Primary Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost
Drug: Timolol 0.5%
Device: Placebo Ocular Insert
Drug: Placebo Eye Drops

First Posted Date: 2015-02-09

Last Posted Date: 2020-06-04

Lead Sponsor: ForSight Vision5, Inc.

Target Recruit Count: 156

Registration Number: NCT02358369

Locations: 🇺🇸
Vold Vision, Fayetteville, Arkansas, United States
🇺🇸
Total Eye Care, Memphis, Tennessee, United States
🇺🇸
University of Eye Specialists, Maryville, Tennessee, United States

and more 7 locations

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost SR
Drug: Timolol Vehicle (placebo)

First Posted Date: 2014-09-26

Last Posted Date: 2021-07-28

Lead Sponsor: Allergan

Target Recruit Count: 528

Registration Number: NCT02250651

Locations: 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
🇺🇸
Mark B. Kislinger, MD, Inc., Glendora, California, United States
🇺🇸
Southern California Eye Physicians and Surgeons, Los Alamitos, California, United States

and more 110 locations

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Timolol Vehicle (placebo)

First Posted Date: 2014-09-25

Last Posted Date: 2020-06-11

Lead Sponsor: Allergan

Target Recruit Count: 594

Registration Number: NCT02247804

Locations: 🇺🇸
Nature Coast Clinical Research, Crystal River, Florida, United States
🇺🇸
Montebello Medical Eye Center Inc., Montebello, California, United States
🇺🇸
Glaucoma Institute of Beverly Hills, Los Angeles, California, United States

and more 103 locations

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Phase 4

Completed

Conditions: Glabellar Lines
Facial Rhytides
Crow's Feet Lines
Nasolabial Fold

Interventions: Biological: onabotulinumtoxinA
Drug: bimatoprost ophthalmic solution 0.03%
Device: JUVÉDERM® ULTRA XC
Device: JUVÉDERM® ULTRA PLUS XC
Device: JUVÉDERM® VOLUMA® XC